Effects of inositol on glucose metabolism in patients with metabolic syndrome
The Action of Inositols and Alpha-lactalbumin on Glucose Metabolism, Arterial Stiffness and Vascular Damage in Patients with Metabolic Syndrome At Risk of Cardiac Fibrosis
This study tests if taking inositol and alpha-lactalbumin can help people with metabolic syndrome improve their blood sugar levels and reduce the risk of heart problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Lo.Li.Pharma s.r.l Industry-sponsored |
| Locations | 1 site (L'Aquila) |
| Trial ID | NCT05689710 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of oral supplementation with inositol and alpha-lactalbumin on key metabolic parameters in individuals diagnosed with metabolic syndrome who are at risk of developing cardiac fibrosis. The intervention aims to improve glucose metabolism and potentially mitigate the risk of cardiac complications associated with metabolic syndrome. Participants will be monitored for changes in metabolic markers throughout the study period.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with metabolic syndrome who meet at least three specific criteria related to triglyceride levels, HDL cholesterol, fasting glycemia, blood pressure, and hip circumference.
Not a fit: Patients who do not meet the criteria for metabolic syndrome or those with established cardiac fibrosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of glucose metabolism in patients with metabolic syndrome, reducing their risk of cardiac fibrosis.
How similar studies have performed: While there is limited information on similar studies, the use of inositol for metabolic conditions has shown promise in preliminary research, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
At least 3 of the following inclusion criteria: * triglycerides levels ≥ 150 mg/dL * HDL ≤ 40 mg/dL * Fasting glycemia \> 100 mg/dL \<126 mg/dl * Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg * Hip circumference \> 102 cm in men or 88 cm in women
Where this trial is running
L'Aquila
- UOC Medicina Interna e Nefrologia P.O. AQ — L'Aquila, Italy (Recruiting)
Study contacts
- Principal investigator: Davide Grassi, MD — UOC Medicina Interna e Nefrologia P.O. AQ
- Study coordinator: Davide Grassi, MD
- Email: davide.grassi@cc.univaq.it
- Phone: +393332123716
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.